Skip to the story
Morning ColumnFree letter

Current News · Sourced report

FDA Approves First Drug Shown to Help Patients with Infantile-Onset Niemann-Pick Disease Type C Live Longer

FDA approved Lembaz (adrabetadex) injection, the first treatment shown to help people with a severe form of Niemann-Pick disease type C (NPC) live longer.

News Desk · Nov 17, 2026 · U.S. Food and Drug Administration

Open the source

This item is a public release from the U.S. Food and Drug Administration. The source date is Nov 17, 2026. The next paragraph is the agency's own short text. Morning Column did not rewrite it.

FDA approved Lembaz (adrabetadex) injection, the first treatment shown to help people with a severe form of Niemann-Pick disease type C (NPC) live longer.

The full release is on the source page. This page is not personal medical advice.

This page is general information from the sources below. It is not personal medical advice, a diagnosis, or a treatment plan. Talk with a qualified clinician about your own health. Read the disclaimer.

References

  1. U.S. Food and Drug Administration. FDA Approves First Drug Shown to Help Patients with Infantile-Onset Niemann-Pick Disease Type C Live Longer. Nov 17, 2026.

See a factual error? Write to contact@morningcolumn.com. The corrections log is public.